XCUR News and Press, Exicure Inc.

WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the Company's Board of Directors at its special meeting held on June 24, 2026. The C...

2026-06-10 16:09:51 ET More on Exicure Most and least shorted healthcare stocks with market cap up to $2B at the end of May Historical earnings data for Exicure Financial information for Exicure Read the full article on Seeking Alpha For further detai...

WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on June 5, 2026 indicating that ...

2026-06-04 09:45:24 ET More on iShares Russell 2000 ETF, iShares Micro-Cap ETF, etc. This K-Shaped Economy Keeps Kicking Time To Take Some Chips Off The Table This Old Bull Still Has Legs Small caps benefiting from AI spending boom, Retzler says—CNBC i...

2026-06-03 09:45:03 ET NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript AI Revolutionizing Biopharma: Faster, Better, Cheaper Trump's Psychedelics Stance Reignites Sector - How Investors Can Benefit Weekly ETFs: Five of 11 sectors...

2026-06-01 16:08:05 ET More on Exicure Historical earnings data for Exicure Financial information for Exicure Read the full article on Seeking Alpha For further details see: Exicure receives Nasdaq notice for delayed Q1 filing

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) --  Exicure, Inc. (Nasdaq: XCUR, the “Company”)  announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 ...

CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multipl...

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following notice: TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF EXICURE, INC. (“EXICURE&#x...

2026-03-26 05:55:53 ET More on Exicure Financial information for Exicure Read the full article on Seeking Alpha For further details see: Exicure GAAP EPS of -$0.79